Carboplatin and Paclitaxel With or Without Cisplatin and Radiation Therapy in Treating Patients With Stage I, Stage II, Stage III, or Stage IVA Endometrial Cancer


Endometrial Clear Cell Adenocarcinoma | Endometrial Serous Adenocarcinoma | Stage IA Uterine Corpus Cancer | Stage IB Uterine Corpus Cancer | Stage II Uterine Corpus Cancer | Stage IIIA Uterine Corpus Cancer | Stage IIIB Uterine Corpus Cancer | Stage IIIC Uterine Corpus Cancer | Stage IVA Uterine Corpus Cancer

What is the purpose of this trial?

This randomized phase III trial studies carboplatin and paclitaxel to see how well they work with or without cisplatin and radiation therapy in treating patients with stage I-IVA endometrial cancer. Drugs used in chemotherapy, such as carboplatin, paclitaxel, and cisplatin, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Radiation therapy uses high-energy x-rays to kill tumor cells. Giving chemotherapy and radiation therapy after surgery may kill any tumor cells that remain after surgery. It is not yet known whether carboplatin and paclitaxel are more effective with or without cisplatin and radiation therapy in treating patients with endometrial cancer.

Participation Guidelines

18 Years - N/A

Click here for detailed information about who can participate in this trial.

Gynecologic Oncology Group
National Cancer Institute (NCI)
June 2009
Last Updated:
December 23, 2014
Study HIC#:

Clinicaltrials.gov ID: NCT00942357